Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 16th Annual BioPharma Virtual Conference – September 8-10, 2021 September 9, 2021 – Arrowhead management will
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
Conference Call and Webcast Today, August 5, 2021 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 5, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2021 . The company is hosting a conference call today,
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
- Full enrollment reached in Phase 2 SEQUOIA study of ARO-AAT PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for ARO-AAT,
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 14, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2021 , at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2021 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 14, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2021 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 42
View HTML
Toggle Summary Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 6, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from the first two cohorts of AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic
View HTML
Toggle Summary Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 2, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 30, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 26, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation
View HTML
Toggle Summary Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 25, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data on the development of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with facioscapulohumeral
View HTML